BangladeshBangladesh is one of South Asia's fastest-growing healthcare markets, with a population exceeding 170 million and a rapidly expanding pharmaceutical and medical device sector. Taevas provides end-to-end DGDA regulatory guidance, distributor access, and co
Select an industry to see regulatory pathways, services, and how Taevas supports your Bangladesh market entry.
Directorate General of Drug Administration (DGDA), Bangladesh
Bangladesh's medical device market is growing steadily, driven by expanding private hospital infrastructure and rising chronic disease burden. The Directorate General of Drug Administration (DGDA) oversees device registration and import licensing under a risk-based classification framework from Class A (lowest risk) to Class D (highest risk). Taevas provides complete regulatory dossier preparation, local agent representation, and commercial support to bring your devices to Bangladeshi healthcare providers efficiently.
All medical devices intended for sale in Bangladesh must be registered with the DGDA. Taevas prepares and submits the full technical dossier aligned with DGDA requirements, including device classification, intended use, and safety data.
Devices are classified Class A through D based on intended use and risk profile. Taevas conducts a pre-submission classification review to determine the correct pathway and documentation requirements before engaging DGDA.
Importation of medical devices into Bangladesh requires a valid import licence issued by DGDA. Taevas manages the full import licence application, coordinating with local authorised agents and customs authorities to ensure uninterrupted supply.
DGDA requires ongoing adverse event reporting and post-market surveillance for registered devices. Taevas maintains your pharmacovigilance and device vigilance obligations, ensuring timely reporting and licence renewal compliance.
Taevas combines deep DGDA regulatory expertise with established distributor networks and KOL relationships built over years of operating in the Bangladesh life-sciences market, giving international brands a faster, lower-risk path to revenue.
Our Bangladesh regulatory team has direct experience navigating DGDA drug and device registration, import licensing, and post-market compliance, reducing submission errors and approval timelines for our clients.
Taevas maintains active relationships with leading distributors, hospital procurement officers, and pharmacy chains across all eight divisions of Bangladesh, giving your products immediate channel access at market entry.
Our structured market entry methodology and pre-built regulatory templates compress the typical Bangladesh entry timeline, enabling life-sciences brands to move from strategy to first commercial sales faster than the market average.
We have vetted and partnered with reputable pharmaceutical, medical device, and consumer health distributors across Bangladesh, ensuring your products reach the right channels with accountable, performance-managed partners.
Taevas has cultivated relationships with key opinion leaders at Bangladesh's leading medical colleges, teaching hospitals, and specialist associations, enabling credible clinical endorsement and evidence-based adoption of your products.
From DGDA dossier submission through warehousing, sales force deployment, and revenue reporting, Taevas operates as a single accountable partner for your entire Bangladesh market entry and growth journey.
Speak with a Taevas Bangladesh specialist to receive a tailored market entry assessment covering DGDA regulatory timelines, distributor options, and a clear path to your first commercial milestone.